Harrold, Leslie R. http://orcid.org/0000-0002-0170-2747
Shan, Ying
Rebello, Sabrina http://orcid.org/0000-0002-0201-4030
Kramer, Neil
Connolly, Sean E.
Alemao, Evo
Kelly, Sheila
Kremer, Joel M. http://orcid.org/0000-0001-6674-9901
Rosenstein, Elliot D. http://orcid.org/0000-0001-7681-4615
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Received: 13 March 2020
Accepted: 5 May 2020
First Online: 24 May 2020
Compliance with ethical standards
:
: Leslie R. Harrold is an employee of Corrona, LLC, a shareholder in Corrona, LLC and has received grant/research support from Pfizer and consulting fees from AbbVie, Bristol Myers Squibb, and Roche. Corrona, LLC has received funds from Bristol Myers Squibb for the analyses. Ying Shan has nothing to disclose. Sabrina Rebello is an employee of Corrona, LLC. Neil Kramer owns stock in AbbVie, Amgen, Johnson & Johnson, Pfizer and Regeneron. Evo Alemao is an employee of Bristol Myers Squibb. Sean E. Connolly and Sheila Kelly have stock options/bond holdings in, and are employees of, Bristol Myers Squibb. Joel Kremer has stock options/bond holdings in, and is an employee of, Corrona, LLC, has received consultancy fees from AbbVie, Amgen, Bristol Myers Squibb, Genentech, Lilly, Regeneron, Sanofi, and Pfizer; grant/research support from AbbVie, Bristol Myers Squibb, Genentech, Lilly, Novartis and Pfizer. Elliot D. Rosenstein reports serving on an advisory board and speakers bureau for Bristol Myers Squibb.
: The database used in this study was the Corrona RA registry. This study was carried out in accordance with the Declaration of Helsinki. All participating investigators were required to obtain full institutional review board approval for conducting non-interventional research involving human subjects. Sponsor approval and continuing review was obtained through a central Institutional Review Board (IRB; New England Independent Review Board, NEIRB No. 120160610). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs and documentation of approval was submitted to Corrona, LLC prior to initiating any study procedures. All registry patients were required to provide written informed consent and authorization prior to participating.
: Consent to participate: All registry patients were required to provide written informed consent and authorization prior to participating. Consent for publication: Not applicable.